FOXO1 inhibition with AS1842856 as a chemotherapeutic for glioblastoma multiforme and basal-like breast cancer
Description
This technology is a targeted therapy for aggressive cancers: basal-like cancer (BBC) and glioblastoma multiforme (GBM). Treatment with AS1842856 was found to induce cell death in a set of cancer lines, BBC: BT 549 and MDA-MB-468 as well as GBM: LN229, DBTRG, A172 and LN18.
Problem
Due to poor survival rate associated with aggressive cancers like BBC and GBM, no current technology exists that can efficaciously treat BBC and GBM cancers.
Solution
A set of cancer lines were treated with AS 1842856 as a therapy for BBC and GBM Results provided evidence of reduced cell numbers, induction of apoptotic genes and induction of apoptosis by membrane permeability (PI staining) and membrane depolarization (Annexin V FITC staining) by flow cytometric analysis.
Value Proposition
FOXO1 inhibition is proposed as a targeted therapy to treat aggressive cancers like BBC and GBM The therapy is effective by reducing cell number, induction of apoptotic genes, and induction of apoptosis.
Competitive Advantages
- Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172,LN 18, HCT116 and SW480 led to reduced colony formation.
- Treatment of a series of cancer cell lines including BT 549, MDA-MB-468, DBTRG, A 172, LN 18, and HCT116 led to apoptotic gene induction.
- Treatment induced apoptosis as assessed by flow cytometric analysis in BT549 and LN229 cancer cell lines.
Status of Development
Prototyping and characterization
IP Status
- Patent protection filed
- Licensing Available
